Oncolytics Biotech Inc T.ONC

ONC One Year Price Chart

[Journeytc]

ONC share price will begin a permanent assent in coming months as it transitions to and becomes a Phase 3 breast cancer company.   Yes pancreatic will reduce financial risk and add value too.  A year ago in June 2023 ONC shares kicked off in anticipation of Phase 3 announcements that never transpired.  After set backs, we now enter a similar period with an additional year of survival data in the Bracelet breast cancer trial and Goblet pancreatic trial.  Final prep and filing for phase three breast cancer trial begins on conclusion of the Type C FDA meeting occurring within the next couple of months.   I don't think ONC will package the company for sale until the matter of 30% dropout of trial participants due to flu symptoms is resolved by the phase 3 trial.  This population potentially doubles value and gains ONC world recognition in paradigm shift in treatment.   They'll never get credit for it until demonstrated.  I personal believe these dropouts were the best responders.

[Journeytc]

We don't have to wait years to get resolution on the 30% of patients in the total population that dropped out and whether they respond.   The phase 3 trial will be designed to give an interim read out.  We already have biomarker results from the AWARE trial that suggest we should be looking at a very high response rate, double what we saw in the Bracelet outcome.   

[Journeytc]

I believe major pharma are prohibited by an ONC NDA from putting in an offer to purchase.   Why?    If I was in the acquisition department a winning lottery ticket would be to find a company with century race horse....Pela......that had an insufferable management team incapable of getting anything across the finish line....ONC.....and with a stock price in the cellar.  I